Skip to main content
. 2022 Jun 16;139(24):3546–3557. doi: 10.1182/blood.2021014520

Figure 5.

Figure 5.

LFS according to baseline risk and MRD status. (A) Unadjusted LFS for all remission cohort patients (n = 192) according to MRD status. (B) LFS for remission cohort patients according to baseline risk status: low (n = 25); intermediate (n = 76); high (n = 40); or very high (n = 50). Patients with MRD-positive remissions are in red, and patients with MRD-negative remissions (all mutations cleared or DT only) are in blue.